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ABSTRACT
Background: Inhaled corticosteroids (ICSs) are widely used in combination with other classes of drugs for
treatment of childhood asthma. The efficacy and the safety of montelukast added to low-dose ICS therapy were
compared with those of sustained-release theophylline added to low-dose ICS therapy in asthmatic children in
the present study.
Methods: Following the 2-week run-in period, 6-to 14-year old patients receiving treatment with ICSs were
randomized to treatment for 4 weeks with either montelukast 5 mg once daily or sustained release theophylline
5―8 mgkg (dry syrup) or 100―200 mg (tablet) twice daily. Patients also received a fixed dose of ICS throughout
the run-in and treatment periods. The primary efficacy endpoint was the change from baseline in peak expira-
tory flow (PEF) at Week 2.
Results: A significant increase in morning PEF was observed in the add-on montelukast group as compared
with the add-on theophylline group at Week 2 (change from baseline of 22.8 Lmin vs. 8.7 Lmin; p = 0.041 for
between-group difference) and at Week 4 (31.0 Lmin vs. 9.8 Lmin; p = 0.012). A significant increase in eve-
ning PEF was observed in the add-on montelukast group as compared with the add-on theophylline group at
Week 4 (24.7 Lmin vs. 8.7 Lmin; p = 0.027). There were no significant differences between the treatment
groups in incidences of clinical and laboratory adverse experiences.
Conclusions: The results indicate that montelukast added to low-dose ICS is an effective and safe option for
the treatment of asthma in children.
KEY WORDS
childhood asthma, inhaled corticosteroid, montelukast, peak expiratory flow, sustained-release theophylline
INTRODUCTION
Bronchial asthma is a chronic inflammatory disease
characterized by airway hyper-responsiveness and
episodic respiratory symptoms, such as breathless-
ness, wheezing, chest tightness and coughing.1,2 Nu-
merous cell types , including eosinophils , T cells ,
mast cells, basophils, and neutrophils, play a role in
triggering airway inflammation . 3 Cysteinyl leukot-
rienes (CysLTs) and other mediators released by
such inflammatory cells have been shown to play a
critical role as determinants of pathological condi-
tions in bronchial asthma.4-6 Montelukast is a selec-
tive CysLT1 receptor antagonist that reduces asth-
matic inflammation and airway resistance and pre-
vents bronchoconstriction.7-10
Inhaled corticosteroids (ICSs) are used as medica-
tion for early intervention and long-term management
of childhood asthma. ICSs are effective because they
directly reach the airway and intensively inhibit air-
way inflammation.11-13 However, when the amount of
drug deposited in the respiratory tract increases with
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Fig. 1 Study design. BDP ＝ beclomethasone dipropionate; 
FP ＝ fluticasone propionate.
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use of higher dose, risks of adverse drug reactions
also increase.11,14 Therefore, some reports have rec-
ommended combination of ICS with other classes of
drugs than ICS monotherapy with increased
doses. 15-17 Such combined therapy for long-term
asthma management has been shown to be more ef-
fective in controlling mild to severe persistent asthma
in children . Candidates for concomitant drugs in-
clude CysLT1 receptor antagonists , long-acting in-
haled β2-agonists, and sustained-release theophylline.
However, there have been few comparative studies
done on these types of drugs when combined with
low-dose ICS in children with asthma. In this study,
the efficacy and safety of oral administration of mon-
telukast was compared to those of sustained-release
theophylline in asthmatic children in the treatment
with ICS.
METHODS
PATIENTS
Eighty-four children, male : 51 (60.7%) , female : 33
(39.3%), aged 6―14 years, with unstable asthma symp-
toms despite low dose ICS therapy were enrolled in
the study . Patients had mild to severe persistent
asthma according to the Japanese Pediatric Guide-
lines11 and mild to moderate persistent asthma as de-
fined by the GINA guidelines. 18 Before the 2-week
run-in period, patients were confirmed to have airway
reversibility and reproducible peak expiratory flow
(PEF) measurement. During the 2-week run-in pe-
riod, patients were confirmed to have symptoms (re-
current coughing, or mild or moderate asthma at-
tacks) . The following patients were excluded from
the study: patients on continuous therapy with oral or
injectable corticosteroids; patients who had used oral
antiallergic drugs within the 2 weeks prior to the run-
in period; patients who used a long-acting corticoster-
oid within the 1 year prior to the run-in period; and
patients with complications that could affect the
evaluation of efficacy , such as bronchiectasis . Pa-
tients with a history of serious adverse drug reaction
to theophylline or other xanthine derivatives and pa-
tients who had previously used montelukast were
also excluded from the study.
Parents or guardians gave written consent prior to
the start of the study. The study was approved by the
institutional review board of each participating site.
STUDY DESIGN
This study was done as a multi-center, randomized,
open-label study conducted between June 2003 and
August 2004. Twenty-four sites around Japan partici-
pated, involving a total of 61 affiliated specialists in pe-
diatric asthma treatment. Following a 2-week run-in
period, patients were randomized to treatment for 4
weeks with either montelukast 5 mg chewable tablet
administered once daily at bedtime or sustained re-
lease theophylline 5―8 mgkg (dry syrup) or 100―200
mg (tablet) twice daily (Fig. 1). Patients also received
a fixed dose of inhaled corticosteroid in the run-in
and treatment periods ( CFC-beclomethasone
dipropionate 100―400 μgday, or fluticasone propion-
ate 100―200 μgday). The central random allocation
of the study drug was performed using the minimiza-
tion method involving study centers and body weight
as factors. Laboratory tests (hematology, blood chem-
istry , urinalysis) were performed at the beginning
and the completion of treatment. Pulmonary function
tests (FEV1 and FVC) were performed at the time of
laboratory tests whenever possible.
EVALUATION OF EFFICACY AND SAFETY
The primary efficacy endpoint was the change from
baseline in PEF at Week 2. PEF was measured daily
with a Mini-Wright PEF meter (Clement Clark Inter-
national; Harlow, UK) three times upon awakening
and three times at bedtime, and the maximum value
at each time was recorded . Patients kept a daily
asthma diary from the beginning of the run-in period
to the completion of treatment , and daily recorded
asthma-related symptoms (asthma attacks, coughing,
daily activities, nighttime sleep), morning and eve-
ning PEF values, treatment compliance with study
medication, and use of other concomitant drugs such
as inhaled β2-agonist.
Clinical and laboratory adverse experiences were
recorded during the study. Patients also assessed tol-
erability at the completion of the 4-week treatment
period (or at discontinuation).
STATISTICAL ANALYSIS
The per-protocol set (PPS) was defined as the pri-
mary efficacy analysis population. The analyses were
also performed in the full analysis set (FAS) to exam-
ine the stability of the study results. Summary statis-
tics of the observed values and the changes from
baseline (defined as the mean over the 2-week run-in
period) as well as their 95% confidence intervals were
288 Allergology International Vol 55, No3, 2006 www.jsaweb.jp
Kondo N et al.
Fig. 2 Comparison of the changes from baseline in morn-
ing and evening PEF between montelukast and theophyline.
＊＊＊p＜0.001 and ＊p＜0.05 compared with baseline.
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Table 1 Patient Demographics and Other Baseline Characteristics (Per-Protocol Set)
TheophylineMontelukastTreatment groups
3639
Number of subjects
N (%)N (%)
Gender
(63.9)23(53.8)21Male
(36.1)13(46.2)18Female
Age
(72.2)26(53.8)216―9 yrs
(27.8)10(46.2)1810―14 yrs
 8.8 ± 2.29.4 ± 2.4Mean ± SD
Body weight
(61.1)22(56.4)22＜ 30 kg
(38.9)14(43.6)17＞＿ 30 kg
28.7 ± 7.834.0 ± 14.3Mean ± SD
Asthma severity
(50.0)18(61.5)24Mild persistent
(44.4)16(30.8)12Moderate persistent
(5.6)2(7.7)3Severe persistent
Duration of asthma
 5.6 ± 3.75.3 ± 3.4Mean ± SD
Dose of inhaled corticosteroid†
(27.8)10(28.2)11＜200 μg/day
(50.0)18(33.3)13＞＿ 200 to 300 μg/day
(22.2)8(38.5)15＞＿ 300 μg/day
235.9 ± 86.5261.6 ± 102.3Mean ± SD
Eosinophils
(47.2)17(30.8)12＜ 6%
(52.8)19(69.2)27＞＿ 6%
†Equivalent to dose of beclomethasone dipropionate
computed at each time point and for each treatment
group. Statistical analyses were performed for PEF at
Week 2 (defined as the mean over treatment between
Week 1 and 2) and Week 4 (defined as mean over
treatment between Week 3 and 4). If there were no
data for analysis at Week 4, then the value at Week 2
was extrapolated, using the Last Observation Carried
Forward method. Comparisons of the change from
baseline between treatment groups were performed
using an analysis-of-covariance model involving treat-
ment as a factor and baseline value as a covariate .
Within-group comparisons of the values at each time
point with baseline were also performed using Stu-
dent’s t-test for the least squares mean (hereinafter
LSmean) of change.
For those patients included in the analysis of
safety, the numbers and percentages of patients re-
porting adverse experiences were summarized by
treatment groups.
RESULTS
Of 84 randomized patients, 79 patients completed the
study, while 5 patients withdrew. The reasons for
withdrawal were: occurrence of adverse experience
in 3 patients, use of prohibited concomitant drug in 1
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Fig. 3 Comparison of the changes from baseline in mild 
asthma atacks between montelukast and theophyline.
＊＊＊p＜0.001, ＊＊p＜0.01, and ＊p＜0.05 compared with 
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Fig. 4 Comparison of the changes from baseline in in-
haled β2-agonist use between montelukast and theophyline.
＊＊p＜0.01 and ＊p＜0.05 compared with baseline.
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Table 2 Summary statistics for PEF (morning, evening), numbers of mild asthma atacks and Inhaled β2-agonist use 
Week 4 (LOCF)Week 4 Week 2BaselineNGroupItem
12.0 ±295.612.0 ±295.611.7 ±287.412.1±264.739MMorning PEF
11.9 ±269.312.0 ±273.112.1 ±270.211.6±261.336T(L/min)
12.0 ±302.512.0 ±302.511.9 ±299.212.3±278.239MEvening PEF
11.4 ±279.212.0 ±278.411.6 ±282.511.5±270.436T(L/min)
0.11±0.270.11±0.270.12±0.280.17±0.8939MMild Asthma Atacks
0.22±0.560.24±0.580.32±0.560.25±1.0236T(times/week)
1.16 ±4.151.16 ±4.151.29 ±4.371.42±5.9326MInhaled β2-Agonist Use
1.91 ±4.581.61 ±3.501.94 ±4.731.76±5.6820T(times/week)
M: Montelukast, T: Theophyline, Mean ± SE
patient, and deviation of study visit schedule in 1 pa-
tient. Seventy-five patients with data on PEF at Week
2 (primary endpoint) were eligible for efficacy analy-
sis . Nine patients were excluded from the efficacy
analysis set, and the reasons for exclusion were: use
of prohibited concomitant drug in 3 patients, violation
of study procedure in 3 patients, change in living en-
vironment in 1 patient, insufficient study period and
insufficient frequency of PEF measurements in 1 pa-
tient , and noncompliance with drug administration
and insufficient frequency of PEF measurements in 1
patient.
Eighty-three patients were eligible for analysis of
safety ; 1 patient in the theophylline group was ex-
cluded because of delayed performance of the pa-
tient’s laboratory tests.
The dose of inhaled corticosteroid (mean ± SD, on
the beclomethasone dipropionate equivalence basis)
in the 75 eligible patients for efficacy analysis was
261.6 ± 102.3 μgday in the montelukast group and
235.9 ± 86.5 μgday in the theophylline group; there
was no significant difference between the two groups.
There were also no significant differences between
the two treatment groups with respect to other base-
line characteristics (including sex, age, body weight,
and severity grade of asthma) (Table 1).
PEF IMPROVEMENT
The LSmean change from the baseline in morning
PEF at Week 2 was 22.8 Lmin in the montelukast
group (p < 0.001: within group comparison from base-
line), and 8.7 Lmin in the theophylline group (p =
0.078: within group comparison from baseline), dem-
onstrating a significant improvement in the montelu-
kast group compared with the theophylline group (p
= 0.041: between group comparison). At Week 4, the
change from baseline in morning PEF was 31.0 L
min in the montelukast group (p < 0.001), and 9.8 L
min in the theophylline group (p = 0.107) , demon-
strating a significant improvement in the montelukast
group compared with the theophylline group (p =
0.012)(Fig. 2, Table 2).
The LSmean change in evening PEF at Week 2
from baseline was 21.3 Lmin in the montelukast
group (p < 0.001) and 11.7 Lmin in the theophylline
group (p = 0.013). The difference between the groups
290 Allergology International Vol 55, No3, 2006 www.jsaweb.jp
Kondo N et al.
in the change from baseline was not significant (p =
0.137). At Week 4, the change from baseline in eve-
ning PEF was 24.7 Lmin in the montelukast
group (p < 0.001) and 8.7 Lmin in the theophylline
group (p = 0.096) , indicating a significant improve-
ment in the montelukast group compared with the
theophylline group (p = 0.027)(Fig. 2, Table 2).
MILD ASTHMA ATTACKS
A mild asthma attack was defined as an episode of
mild wheezing occasionally associated with mild in-
tercostal or tracheosternal retractions. The LSmean
change from the baseline in the number of mild
asthma attacks (including wheezing) at Week 2 was
−0.64 timesweek in the montelukast group (p =
0.004 for difference from baseline) and −0.42 times
week in the theophylline group (p = 0.061 for differ-
ence from baseline). The change at Week 4 was −0.68
timesweek in the montelukast group (p < 0.001) and
−0.41 timesweek in the theophylline group (p =
0.024). No significant differences between the groups
were observed in the changes at Week 2 and Week 4
(Fig. 3, Table 2).
INHALED β2-AGONIST USE
The LSmean change from baseline in the number of
inhaled β2-agonist use at Week 2 was −1.55 times
week in the montelukast group (p = 0.046) and −0.98
timesweek in the theophylline group (p = 0.261) .
The change at Week 4 was −1.69 timesweek in the
montelukast group (p = 0.005) and −1.41 timesweek
in the theophylline group (p = 0.044). No significant
differences between the groups were observed in the
changes at Week 2 and Week 4(Fig. 4, Table 2).
PERIPHERAL BLOOD EOSINOPHILS
Eosinophil levels were not significantly affected by
either treatment with add-on montelukast or theo-
phylline and no significant difference was observed
between the two treatments (data not shown).
SUBGROUP ANALYSIS BY BODY WEIGHT IN
THE MONTELUKAST GROUP
Study subjects on montelukast were stratified into
subgroups by body weight (<30 kg and30 kg), and
differences in PEF and in safety were assessed. The
changes from baseline values in morning and eve-
ning PEF were similar between the subgroups at
Week 2 and Week 4; there were also no significant
differences between the two subgroups in safety as-
sessments (data not shown).
SAFETY ASSESSMENT
There were no clinically meaningful differences be-
tween the treatment groups in the incidence of clini-
cal or laboratory adverse experiences . Two drug-
related clinical adverse experiences were seen but
they were mild and transient: 1 patient (2.4%) in the
montelukast group developed headache and 1 patient
(2.4%) in the theophylline group had queasiness. Two
serious clinical adverse events , status asthmaticus
and asthma aggravation, were reported in 1 patient in
each treatment group ; however , these were not
judged to be drug-related. Two patients (4.8%) in the
montelukast group developed drug-related laboratory
adverse experiences : 1 patient had increased total
protein (baseline: 6.8 gdL, Week 4: 8.7 gdL, normal
range value: 6.3―7.9 gdL); 1 patient had increased
total bilirubin (baseline: 0.9 mgdL, Week 4: 1.7 mg
dL, normal range value: 0.1―1.0 mgdL) and positive
urobilinogen urine (baseline: ±, Week 4: +, normal
range value: ±). Drug-related serious laboratory ad-
verse experiences were not reported. No drug-related
adverse experiences were clinically significant.
DISCUSSION
Theophylline is a widely used medication for the
treatment of asthma, mostly because of its ease of
use, low cost and good anti-inflammatory effects ; 19
thus, it was selected for a positive control, as an add-
on agent to ICS in this study. In this study, the mean
theophylline dosage was 9.8 mgkgday (4.7―15.7
mgkgday). Sugimoto et al. reported that the mean
serum theophylline concentration was 8.8―13.1 μg
ml when 7-to 10-year old asthmatic children were
given theophylline at a dose of 16 mgkgday in the
steady state.20 In addition, Nakashima et al. reported
that the mean serum theophylline concentration was
5.5―7.3 μgml when healthy adult male subjects were
administered 400 mgday ( approximately 6.1 mg
kgday) in the steady state.21 The ranges of serum
theophylline concentration in the present study were
assumed to be between the values of the above two
studies . 20,21 In this study , the investigators deter-
mined whether or not to perform serum concentra-
tion measurement for patients mainly consisting of
those whose asthma symptoms were not improved.
As a result, the serum theophylline concentration was
measured in three patients: 1.3 and 3.1 μgml (this
patient was measured twice at a dose of 8.2 mgkg
day ) , under the detection limit of 2.0 μgml
(10.4 mgkgday), and 6.5 μgml (12.0 mgkgday),
respectively. When used as complementary therapy
in patients not optimally controlled by low-to-high
dose ICS, montelukast has shown to improve the con-
trol of asthma and reduce exacerbations, and to be a
good alternative to increasing a dose of ICS or given
an additional long-acting β2-agonist.22,23
This study shows that montelukast plus ICS dem-
onstrated significant improvement in morning and
evening PEF at week 2 and 4 compared to the base-
line results with ICS alone . Theophylline plus ICS
demonstrated significant improvement in evening
PEF at Week 2, compared to the baseline value. Chil-
dren administered concomitant montelukast and ICS
demonstrated a significantly greater improvement in
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morning PEF at Week 2 and morning and evening
PEF at Week 4 in comparison with concomitant treat-
ment of theophylline and ICS. The improvement in
PEF observed with add-on montelukast in the early
stage within 2 weeks of the therapy is consistent with
the results of a study in adult patients with bronchial
asthma , who reported significant improvement in
morning PEF from its baseline after 1―3 days of ther-
apy with add-on montelukast.22
To investigate the influence of severity and dura-
tion of disease, subgroup analyses by severity (mild
vs. moderate and severe) and duration of disease (<5
years vs.5 years) were performed. In all the sub-
groups, montelukast showed significant improvement
from baseline at Week 2 in the morning PEF ,
whereas theophylline did not ( data not shown ) .
These findings indicate that the addition of montelu-
kast to the therapy resulted in improvement in PEF
as early as Week 2, independent of the severity and
duration of disease.
Diurnal variation in PEF is an useful indicator for
evaluation of asthma, which is possibly related to air-
way hyper-responsiveness . 24 The exploratory data
analysis demonstrated that the mean diurnal variation
in PEF decreased in the montelukast group from the
baseline value of 9.3 ± 5.2% to 7.2 ± 4.2% at Week 2 (p
= 0.005), to 6.1 ± 3.6% at Week 4 (p < 0.001), however
it was unchanged in the theophylline group (baseline:
8.8 ± 7.3%, Week 2: 9.0 ± 9.0, p = 0.794, Week 4: 7.3 ±
5.0, p = 0.077). The result suggested that the addition
of montelukast to ICS provided more improvement
for diurnal variation in PEF than theophylline.
A reduction in mild asthma attacks and in β2-
agonist use is indicative of improvement in asthma
control. Add-on montelukast further reduced the fre-
quency of mild asthma attacks (compared to baseline
values) throughout the study, while add-on theophyl-
line was more effective only at Week 4. Also, inhaled
β2-agonist use during Week 2 or Week 4 (compared
to baseline use) was significantly reduced with add-
on montelukast , but not with add-on theophylline .
These results suggest that montelukast added to ICS
can decrease asthma-related symptoms more than
theophylline added to ICS in asthmatic children .
Therefore, it is concluded that montelukast is more
effective than theophylline as add-on therapy to low
dose ICS in improving pulmonary measures and
asthma-related symptoms in asthmatic children.
Peripheral blood eosinophil levels serve as an indi-
cator of airway inflammation.25 Montelukast is known
to decrease peripheral blood eosinophil levels . 26
However, eosinophil levels did not show any signifi-
cant change from the baseline value in both treat-
ment groups in this study. It is thought that the num-
ber of patients might not be sufficient to demonstrate
significant change.
Montelukast showed additional improvement in
PEF to ICS alone because it is believed to have differ-
ent mechanisms of action from those of ICS in sup-
pressing airway inflammation. It is known that de-
spite treatment with corticosteroids, airway inflamma-
tion persists in asthmatic patients.27 While ICSs affect
many inflammatory pathways in asthma, they have lit-
tle impact on CysLTs . 28 The results from several
large-scale clinical studies provide support for this
view of a dual pathway of airway inflammation.22,23,29
Montelukast is indicated with one dose of 5 mg for
6-to 14-year old patients , in whom body weight
ranged widely. Therefore, in this study the influence
of body weight was investigated . The efficacy and
safety results from stratifying patients into subgroups
(<30 kg and 30 kg) confirmed the appropriateness
of the use of one dose for pediatric patients in that
age range. The recent study, which was a multicen-
ter, randomized, double-blind trial for 6-to 14-year old
patients with mild asthma, revealed that the efficacy
and safety did not differ greatly regardless of body
weight when 5 mg montelukast was administrated.30
During four weeks of treatment in children with
asthma on ICS therapy, both montelukast and theo-
phylline showed a favorable safety profile. In addition,
the MOSAIC study,31 which was a 12-month, multi-
center, randomized, double-blind trial for 6-to 14-year
old patients with mild asthma, showed that montelu-
kast was generally well tolerated for the treatment pe-
riod (12-months), clinical and laboratory drug-related
adverse experience represented 4.4% and 0.5% in the
montelukast group, respectively.
In summary, this study suggests that when com-
bined with ICS therapy, montelukast is an effective
and safe option for long-term management of child-
hood asthma. Furthermore, taking into account the
mode of administration, dose management and con-
venience of handling , montelukast may be consid-
ered superior to sustained-release theophylline as
add-on therapy to ICS in asthmatic children.
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